OmniAb (OABI) Q2 FY26 earnings call

OmniAb delivered a strong Q2 FY26, driven by significant milestone revenue from advancing partner programs and initial sales of its novel Exploration platform. The company raised its full-year revenue and cash guidance, reflecting confidence in its differentiated antibody discovery technologies and the growing pipeline of clinical-stage assets. Management emphasized the long-term potential of royalties and the scalable infrastructure to drive future profitability.